Cargando…

Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?

Malaria remains a major global health burden, killing hundreds of thousands annually, especially in sub-Saharan Africa. In 2019, a Phase IV Expanded Programme on Immunization (EPI)-linked malaria vaccine implementation was underway. However, in December 2019, a novel pneumonia condition termed coron...

Descripción completa

Detalles Bibliográficos
Autores principales: Nghochuzie, Nora Nganyewo, Olwal, Charles Ochieng', Udoakang, Aniefiok John, Amenga-Etego, Lucas Naam-Kayagre, Amambua-Ngwa, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314964/
https://www.ncbi.nlm.nih.gov/pubmed/32625198
http://dx.doi.org/10.3389/fmicb.2020.01476
_version_ 1783550164671135744
author Nghochuzie, Nora Nganyewo
Olwal, Charles Ochieng'
Udoakang, Aniefiok John
Amenga-Etego, Lucas Naam-Kayagre
Amambua-Ngwa, Alfred
author_facet Nghochuzie, Nora Nganyewo
Olwal, Charles Ochieng'
Udoakang, Aniefiok John
Amenga-Etego, Lucas Naam-Kayagre
Amambua-Ngwa, Alfred
author_sort Nghochuzie, Nora Nganyewo
collection PubMed
description Malaria remains a major global health burden, killing hundreds of thousands annually, especially in sub-Saharan Africa. In 2019, a Phase IV Expanded Programme on Immunization (EPI)-linked malaria vaccine implementation was underway. However, in December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with many clinical, epidemiological, and biological parallels to malaria, was reported in Wuhan, China. COVID-19 is spreading rapidly, and, as of the 3rd of June, 2020, more than 382,507 persons had died from COVID-19. Children under 5 years who suffer high malaria-attributable mortalities are largely asymptomatic for COVID-19. Considering that the malaria burden is highest in low-income tropical countries with little capacity to fund malaria control and eradication programs, the fight against malaria in these regions is likely to be hampered. Access to healthcare has generally been limited, while malaria interventions, such as seasonal malaria chemotherapy and distribution of insecticide-treated bed nets, have been suspended due to lockdowns. Likewise, the repurposing of antimalarials for treatment of COVID-19 shared symptoms and the shift in focus from the production of malaria rapid diagnostic tests (RDTs) to COVID-19 RDTs is a cause for concern in malaria-endemic regions. Children are less affected by the COVID-19 pandemic compared to the elderly. However, due to the fears of contracting SARS-CoV-2, the elderly who are worst affected by COVID-19 may not take children for malaria medication, resulting in high malaria-related mortalities among children. COVID-19 has disproportionately affected developed countries, threatening their donation capacity. These are likely to thwart malaria control efforts in low-income regions. Here, we present perspectives on the collateral impact of COVID-19 on malaria, especially in Africa.
format Online
Article
Text
id pubmed-7314964
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73149642020-07-02 Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak? Nghochuzie, Nora Nganyewo Olwal, Charles Ochieng' Udoakang, Aniefiok John Amenga-Etego, Lucas Naam-Kayagre Amambua-Ngwa, Alfred Front Microbiol Microbiology Malaria remains a major global health burden, killing hundreds of thousands annually, especially in sub-Saharan Africa. In 2019, a Phase IV Expanded Programme on Immunization (EPI)-linked malaria vaccine implementation was underway. However, in December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with many clinical, epidemiological, and biological parallels to malaria, was reported in Wuhan, China. COVID-19 is spreading rapidly, and, as of the 3rd of June, 2020, more than 382,507 persons had died from COVID-19. Children under 5 years who suffer high malaria-attributable mortalities are largely asymptomatic for COVID-19. Considering that the malaria burden is highest in low-income tropical countries with little capacity to fund malaria control and eradication programs, the fight against malaria in these regions is likely to be hampered. Access to healthcare has generally been limited, while malaria interventions, such as seasonal malaria chemotherapy and distribution of insecticide-treated bed nets, have been suspended due to lockdowns. Likewise, the repurposing of antimalarials for treatment of COVID-19 shared symptoms and the shift in focus from the production of malaria rapid diagnostic tests (RDTs) to COVID-19 RDTs is a cause for concern in malaria-endemic regions. Children are less affected by the COVID-19 pandemic compared to the elderly. However, due to the fears of contracting SARS-CoV-2, the elderly who are worst affected by COVID-19 may not take children for malaria medication, resulting in high malaria-related mortalities among children. COVID-19 has disproportionately affected developed countries, threatening their donation capacity. These are likely to thwart malaria control efforts in low-income regions. Here, we present perspectives on the collateral impact of COVID-19 on malaria, especially in Africa. Frontiers Media S.A. 2020-06-18 /pmc/articles/PMC7314964/ /pubmed/32625198 http://dx.doi.org/10.3389/fmicb.2020.01476 Text en Copyright © 2020 Nghochuzie, Olwal, Udoakang, Amenga-Etego and Amambua-Ngwa. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Nghochuzie, Nora Nganyewo
Olwal, Charles Ochieng'
Udoakang, Aniefiok John
Amenga-Etego, Lucas Naam-Kayagre
Amambua-Ngwa, Alfred
Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?
title Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?
title_full Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?
title_fullStr Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?
title_full_unstemmed Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?
title_short Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?
title_sort pausing the fight against malaria to combat the covid-19 pandemic in africa: is the future of malaria bleak?
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314964/
https://www.ncbi.nlm.nih.gov/pubmed/32625198
http://dx.doi.org/10.3389/fmicb.2020.01476
work_keys_str_mv AT nghochuzienoranganyewo pausingthefightagainstmalariatocombatthecovid19pandemicinafricaisthefutureofmalariableak
AT olwalcharlesochieng pausingthefightagainstmalariatocombatthecovid19pandemicinafricaisthefutureofmalariableak
AT udoakanganiefiokjohn pausingthefightagainstmalariatocombatthecovid19pandemicinafricaisthefutureofmalariableak
AT amengaetegolucasnaamkayagre pausingthefightagainstmalariatocombatthecovid19pandemicinafricaisthefutureofmalariableak
AT amambuangwaalfred pausingthefightagainstmalariatocombatthecovid19pandemicinafricaisthefutureofmalariableak